BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58:949-55. [PMID: 23333527 DOI: 10.1016/j.jhep.2013.01.003] [Cited by in Crossref: 359] [Cited by in F6Publishing: 357] [Article Influence: 39.9] [Reference Citation Analysis]
Number Citing Articles
1 Doycheva I, Leise MD, Watt KD. The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. Transplantation. 2016;100:61-68. [PMID: 26647107 DOI: 10.1097/tp.0000000000001008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
2 Allaband C, Lingaraju A, Martino C, Russell B, Tripathi A, Poulsen O, Dantas Machado AC, Zhou D, Xue J, Elijah E, Malhotra A, Dorrestein PC, Knight R, Haddad GG, Zarrinpar A. Intermittent Hypoxia and Hypercapnia Alter Diurnal Rhythms of Luminal Gut Microbiome and Metabolome. mSystems 2021;:e0011621. [PMID: 34184915 DOI: 10.1128/mSystems.00116-21] [Reference Citation Analysis]
3 Torres J, Palmela C, Brito H, Bao X, Ruiqi H, Moura-Santos P, Pereira da Silva J, Oliveira A, Vieira C, Perez K, Itzkowitz SH, Colombel JF, Humbert L, Rainteau D, Cravo M, Rodrigues CM, Hu J. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J. 2018;6:112-122. [PMID: 29435321 DOI: 10.1177/2050640617708953] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
4 Golonka R, Yeoh BS, Vijay-Kumar M. Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health. Curr Pharmacol Rep 2019;5:303-16. [PMID: 32864300 DOI: 10.1007/s40495-019-00187-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Ma J, Hong Y, Zheng N, Xie G, Lyu Y, Gu Y, Xi C, Chen L, Wu G, Li Y, Tao X, Zhong J, Huang Z, Wu W, Yuan L, Lin M, Lu X, Zhang W, Jia W, Sheng L, Li H. Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically. Gut Microbes 2020;11:1450-74. [PMID: 32515683 DOI: 10.1080/19490976.2020.1763770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
6 Peña-Rodríguez M, Vega-Magaña N, García-Benavides L, Zepeda-Nuño JS, Gutierrez-Silerio GY, González-Hernández LA, Andrade-Villanueva JF, Del Toro-Arreola S, Pereira-Suárez AL, Bueno-Topete MR. Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model. J Appl Microbiol 2021. [PMID: 33982373 DOI: 10.1111/jam.15135] [Reference Citation Analysis]
7 Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G, Namkoong H, Bittinger K, Fischbach MA, Sonnenburg JL, Habtezion A. Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. Cell Host Microbe 2020;27:659-670.e5. [PMID: 32101703 DOI: 10.1016/j.chom.2020.01.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 31.0] [Reference Citation Analysis]
8 Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP. Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol 2016; 8(27): 1128-1136 [PMID: 27721918 DOI: 10.4254/wjh.v8.i27.1128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
9 Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 2017;101:47-64. [PMID: 27888332 DOI: 10.1007/s00253-016-8006-6] [Cited by in Crossref: 184] [Cited by in F6Publishing: 159] [Article Influence: 30.7] [Reference Citation Analysis]
10 Das P, Marcišauskas S, Ji B, Nielsen J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics 2019;20:517. [PMID: 31234773 DOI: 10.1186/s12864-019-5899-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
11 Buechler C, Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158658. [PMID: 32058031 DOI: 10.1016/j.bbalip.2020.158658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
12 Sanborn V, Gunstad J. The Potential Mediation of the Effects of Physical Activity on Cognitive Function by the Gut Microbiome. Geriatrics (Basel) 2020;5:E63. [PMID: 32992812 DOI: 10.3390/geriatrics5040063] [Reference Citation Analysis]
13 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
14 Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther 2019;49:183-93. [PMID: 30506692 DOI: 10.1111/apt.15035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
15 Nakatani A, Li X, Miyamoto J, Igarashi M, Watanabe H, Sutou A, Watanabe K, Motoyama T, Tachibana N, Kohno M, Inoue H, Kimura I. Dietary mung bean protein reduces high-fat diet-induced weight gain by modulating host bile acid metabolism in a gut microbiota-dependent manner. Biochem Biophys Res Commun 2018;501:955-61. [PMID: 29777704 DOI: 10.1016/j.bbrc.2018.05.090] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 7.8] [Reference Citation Analysis]
16 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
17 Bao Q, Yu L, Chen D, Li L. Variation in the gut microbial community is associated with the progression of liver regeneration. Hepatol Res 2020;50:121-36. [PMID: 31465626 DOI: 10.1111/hepr.13424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
19 Vaikunthanathan T, Safinia N, Lombardi G, Lechler RI. Microbiota, immunity and the liver. Immunol Lett. 2016;171:36-49. [PMID: 26835593 DOI: 10.1016/j.imlet.2016.01.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
20 Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, Sobolev AP, Circi S, Giannelli V, Mannina L, Schippa S, Merli M. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep 2018;8:8210. [PMID: 29844325 DOI: 10.1038/s41598-018-26509-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
21 Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014;39:1113-25. [PMID: 24628464 DOI: 10.1111/apt.12695] [Cited by in Crossref: 152] [Cited by in F6Publishing: 146] [Article Influence: 19.0] [Reference Citation Analysis]
22 Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Sci Rep. 2016;6:26800. [PMID: 27225869 DOI: 10.1038/srep26800] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 15.0] [Reference Citation Analysis]
23 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
24 Lu H, Chen L, Pan X, Yao Y, Zhang H, Zhu X, Lou X, Zhu C, Wang J, Li L, Wu Z. Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients. Front Med (Lausanne) 2021;8:762930. [PMID: 34722597 DOI: 10.3389/fmed.2021.762930] [Reference Citation Analysis]
25 Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol. 2013;59:571-582. [PMID: 23603668 DOI: 10.1016/j.jhep.2013.03.015] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 8.6] [Reference Citation Analysis]
26 Karlsen TH, Vesterhus M, Boberg KM. Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther 2014;39:282-301. [DOI: 10.1111/apt.12581] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
27 Zhang C, Ma S, Wu J, Luo L, Qiao S, Li R, Xu W, Wang N, Zhao B, Wang X, Zhang Y, Wang X. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin. Pharmacol Res 2020;159:104985. [PMID: 32504839 DOI: 10.1016/j.phrs.2020.104985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Lee SM, Kim N, Yoon H, Kim YS, Choi SI, Park JH, Lee DH. Compositional and Functional Changes in the Gut Microbiota in Irritable Bowel Syndrome Patients. Gut Liver 2021;15:253-61. [PMID: 32457278 DOI: 10.5009/gnl19379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
30 Reid D, Mcdonald B, Khalid T, Vo T, Schenck L, Surette M, Beck P, Reimer R, Probert C, Rioux K, Eksteen B. Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2016;1862:1337-44. [DOI: 10.1016/j.bbadis.2016.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Zeng B, Han S, Wang P, Wen B, Jian W, Guo W, Yu Z, Du D, Fu X, Kong F, Yang M, Si X, Zhao J, Li Y. The bacterial communities associated with fecal types and body weight of rex rabbits. Sci Rep 2015;5:9342. [PMID: 25791609 DOI: 10.1038/srep09342] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
32 Hamid H, Zhang JY, Li WX, Liu C, Li ML, Zhao LH, Ji C, Ma QG. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. Poult Sci 2019;98:2509-21. [PMID: 30690636 DOI: 10.3382/ps/pey596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
34 Kim SE, Park JW, Kim HS, Jang MK, Suk KT, Kim DJ. The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. Int J Mol Sci 2021;22:11680. [PMID: 34769109 DOI: 10.3390/ijms222111680] [Reference Citation Analysis]
35 Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, Holvoet T, Vilchez-Vargas R, Vital M, Pieper DH, Vanden Bussche J, Vanhaecke L, Van de Wiele T, De Vos M, Laukens D. Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice. Appl Environ Microbiol 2017;83:e02766-16. [PMID: 28115375 DOI: 10.1128/AEM.02766-16] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
36 Tsuei J, Chau T, Mills D, Wan YJ. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood) 2014;239:1489-504. [PMID: 24951470 DOI: 10.1177/1535370214538743] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
37 Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig Dis 2015;33:338-45. [PMID: 26045267 DOI: 10.1159/000371678] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
38 Rodriguez-Gonzalez A, Orio L. Microbiota and Alcohol Use Disorder: Are Psychobiotics a Novel Therapeutic Strategy? Curr Pharm Des 2020;26:2426-37. [PMID: 31969090 DOI: 10.2174/1381612826666200122153541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
39 Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep 2021;3:100220. [PMID: 33598648 DOI: 10.1016/j.jhepr.2020.100220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health 2021;18:12836. [PMID: 34886561 DOI: 10.3390/ijerph182312836] [Reference Citation Analysis]
41 Li N, Zhan S, Tian Z, Liu C, Xie Z, Zhang S, Chen M, Zeng Z, Zhuang X. Alterations in Bile Acid Metabolism Associated With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izaa342. [PMID: 33399195 DOI: 10.1093/ibd/izaa342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Chen Y, Qin N, Guo J, Qian G, Fang D, Shi D, Xu M, Yang F, He Z, Van Nostrand JD. Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics. 2014;15:753. [PMID: 25179593 DOI: 10.1186/1471-2164-15-753] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
43 Sidhu SS, Goyal O, Kishore H, Sidhu S. New paradigms in management of alcoholic hepatitis: a review. Hepatol Int 2017;11:255-67. [PMID: 28247264 DOI: 10.1007/s12072-017-9790-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
44 Jose S, Mukherjee A, Horrigan O, Setchell KDR, Zhang W, Moreno-Fernandez ME, Andersen H, Sharma D, Haslam DB, Divanovic S, Madan R. Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice. Mucosal Immunol 2021;14:500-10. [PMID: 32811993 DOI: 10.1038/s41385-020-00338-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Camilleri M, Vella A. What to do about the leaky gut. Gut 2021:gutjnl-2021-325428. [PMID: 34509978 DOI: 10.1136/gutjnl-2021-325428] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes Obes Metab. 2016;18:444-453. [PMID: 26818734 DOI: 10.1111/dom.12637] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
47 Liu HX, Rocha CS, Dandekar S, Wan YJ. Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration. J Hepatol 2016;64:641-50. [PMID: 26453969 DOI: 10.1016/j.jhep.2015.09.022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
48 Macnaughtan J, Jalan R. Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. American Journal of Gastroenterology 2015;110:1399-410. [DOI: 10.1038/ajg.2015.313] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
49 You W, Zhu Y, Wei A, Du J, Wang Y, Zheng P, Tu M, Wang H, Wen L, Yang X. Traumatic Brain Injury Induces Gastrointestinal Dysfunction and Dysbiosis of Gut Microbiota Accompanied by Alterations of Bile Acid Profile. J Neurotrauma 2021. [PMID: 33677989 DOI: 10.1089/neu.2020.7526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther. 2015;42:802-817. [PMID: 26223936 DOI: 10.1111/apt.13333] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
51 Lv LX, Fang DQ, Shi D, Chen DY, Yan R, Zhu YX, Chen YF, Shao L, Guo FF, Wu WR, Li A, Shi HY, Jiang XW, Jiang HY, Xiao YH, Zheng SS, Li LJ. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol. 2016;18:2272-2286. [PMID: 27243236 DOI: 10.1111/1462-2920.13401] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 19.2] [Reference Citation Analysis]
52 Cai FF, Wu R, Song YN, Xiong AZ, Chen XL, Yang MD, Yang L, Hu Y, Sun MY, Su SB. Yinchenhao Decoction Alleviates Liver Fibrosis by Regulating Bile Acid Metabolism and TGF-β/Smad/ERK Signalling Pathway. Sci Rep 2018;8:15367. [PMID: 30337590 DOI: 10.1038/s41598-018-33669-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
53 Villette R, Kc P, Beliard S, Salas Tapia MF, Rainteau D, Guerin M, Lesnik P. Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels. Front Pharmacol 2020;11:278. [PMID: 32308619 DOI: 10.3389/fphar.2020.00278] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
54 Oh YJ, Nam K, Kim Y, Lee SY, Kim HS, Kang JI, Lee SY, Hwang KT. Effect of a Nutritionally Balanced Diet Comprising Whole Grains and Vegetables Alone or in Combination with Probiotic Supplementation on the Gut Microbiota. Prev Nutr Food Sci 2021;26:121-31. [PMID: 34316477 DOI: 10.3746/pnf.2021.26.2.121] [Reference Citation Analysis]
55 Khan TJ, Hasan MN, Azhar EI, Yasir M. Association of gut dysbiosis with intestinal metabolites in response to antibiotic treatment. Human Microbiome Journal 2019;11:100054. [DOI: 10.1016/j.humic.2018.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med 2018;215:383-96. [PMID: 29339445 DOI: 10.1084/jem.20171965] [Cited by in Crossref: 127] [Cited by in F6Publishing: 118] [Article Influence: 31.8] [Reference Citation Analysis]
57 Chen W, Wei Y, Xiong A, Li Y, Guan H, Wang Q, Miao Q, Bian Z, Xiao X, Lian M, Zhang J, Li B, Cao Q, Fan Z, Zhang W, Qiu D, Fang J, Gershwin ME, Yang L, Tang R, Ma X. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.Clin Rev Allergy Immunol. 2020;58:25-38. [PMID: 30900136 DOI: 10.1007/s12016-019-08731-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
58 Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, Zhao J, Zhang H, Chen W. Blautia-a new functional genus with potential probiotic properties? Gut Microbes 2021;13:1-21. [PMID: 33525961 DOI: 10.1080/19490976.2021.1875796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
59 Tang W, Yao X, Xia F, Yang M, Chen Z, Zhou B, Liu Q. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018;2018:7261619. [PMID: 30671174 DOI: 10.1155/2018/7261619] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
60 Ferrere G, Wrzosek L, Cailleux F, Turpin W, Puchois V, Spatz M, Ciocan D, Rainteau D, Humbert L, Hugot C, Gaudin F, Noordine M, Robert V, Berrebi D, Thomas M, Naveau S, Perlemuter G, Cassard A. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. Journal of Hepatology 2017;66:806-15. [DOI: 10.1016/j.jhep.2016.11.008] [Cited by in Crossref: 127] [Cited by in F6Publishing: 119] [Article Influence: 25.4] [Reference Citation Analysis]
61 Verdier J, Luedde T, Sellge G. Biliary Mucosal Barrier and Microbiome. Viszeralmedizin. 2015;31:156-161. [PMID: 26468308 DOI: 10.1159/000431071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
62 Zhao J, Zhang QL, Shen JH, Wang K, Liu J. Magnesium lithospermate B improves the gut microbiome and bile acid metabolic profiles in a mouse model of diabetic nephropathy. Acta Pharmacol Sin 2019;40:507-13. [PMID: 29941869 DOI: 10.1038/s41401-018-0029-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
63 Wang X, Xie G, Zhao A, Zheng X, Huang F, Wang Y, Yao C, Jia W, Liu P. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. J Proteome Res 2016;15:1126-34. [PMID: 25964117 DOI: 10.1021/acs.jproteome.5b00217] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
64 Huan H, Ren T, Xu L, Hu H, Liu C. Compositional distinction of gut microbiota between Han Chinese and Tibetan populations with liver cirrhosis. PeerJ 2021;9:e12142. [PMID: 34616612 DOI: 10.7717/peerj.12142] [Reference Citation Analysis]
65 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? World J Clin Cases 2021; 9(31): 9320-9332 [PMID: 34877269 DOI: 10.12998/wjcc.v9.i31.9320] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234-44. [DOI: 10.1007/s12072-019-09932-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
67 Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, Monma T, Konishi N, Yara S, Hirayama T, Miyazaki T, Saito Y, Ikegami T, Matsuzaki Y. Detection of Gut Dysbiosis due to Reduced Clostridium Subcluster XIVa Using the Fecal or Serum Bile Acid Profile. Inflamm Bowel Dis 2018;24:1035-44. [PMID: 29688473 DOI: 10.1093/ibd/izy022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
68 Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev 2021;:e13316. [PMID: 34279051 DOI: 10.1111/obr.13316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
69 Chung BK, Karlsen TH, Folseraas T. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1390-1400. [PMID: 28844951 DOI: 10.1016/j.bbadis.2017.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
70 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Zhang J, Xiong F, Wang G, Li W, Li M, Zou H, Wu S. The influence of diet on the grass carp intestinal microbiota and bile acids. Aquac Res 2017;48:4934-44. [DOI: 10.1111/are.13312] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
72 Dollé L, de La Serre CB, van Grunsven LA. Are dietary emulsifiers making us fat? Journal of Hepatology 2015;63:1045-8. [DOI: 10.1016/j.jhep.2015.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
73 Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol 2019;16:235-46. [DOI: 10.1038/s41575-018-0099-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 120] [Article Influence: 40.7] [Reference Citation Analysis]
74 Dai X, He L, Hu N, Guo C, Zhou M, Zhao X, Wang C, Gong L, Ma C, Xue X, Li Y. Polygoni Multiflori Radix Praeparata Ethanol Extract Exerts a Protective Effect Against High-Fat Diet Induced Non-Alcoholic Fatty Liver Disease in Mice by Remodeling Intestinal Microbial Structure and Maintaining Metabolic Homeostasis of Bile Acids. Front Pharmacol 2021;12:734670. [PMID: 34867343 DOI: 10.3389/fphar.2021.734670] [Reference Citation Analysis]
75 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
76 Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474:1823-1836. [PMID: 28512250 DOI: 10.1042/bcj20160510] [Cited by in Crossref: 714] [Cited by in F6Publishing: 401] [Article Influence: 142.8] [Reference Citation Analysis]
77 Enright EF, Griffin BT, Gahan CG, Joyce SA. Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. Pharmacological Research 2018;133:170-86. [DOI: 10.1016/j.phrs.2018.04.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
78 Fernández J, Tandon P, Mensa J, Garcia-tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology 2016;63:2019-31. [DOI: 10.1002/hep.28330] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 16.0] [Reference Citation Analysis]
79 Huang ZA, Chen X, Zhu Z, Liu H, Yan GY, You ZH, Wen Z. PBHMDA: Path-Based Human Microbe-Disease Association Prediction. Front Microbiol 2017;8:233. [PMID: 28275370 DOI: 10.3389/fmicb.2017.00233] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
80 Li S, Song J, Ke P, Kong L, Lei B, Zhou J, Huang Y, Li H, Li G, Chen J, Li X, Xiang Z, Ning Y, Wu F, Wu K. The gut microbiome is associated with brain structure and function in schizophrenia. Sci Rep 2021;11:9743. [PMID: 33963227 DOI: 10.1038/s41598-021-89166-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
81 Cameron SJS, Alexander JL, Bolt F, Burke A, Ashrafian H, Teare J, Marchesi JR, Kinross J, Li JV, Takáts Z. Evaluation of Direct from Sample Metabolomics of Human Feces Using Rapid Evaporative Ionization Mass Spectrometry. Anal Chem 2019;91:13448-57. [DOI: 10.1021/acs.analchem.9b02358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
82 Dunn W, Shah VH. Pathogenesis of Alcoholic Liver Disease. Clin Liver Dis. 2016;20:445-456. [PMID: 27373608 DOI: 10.1016/j.cld.2016.02.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
83 Gómez-Hurtado I, Such J, Francés R. Microbiome and bacterial translocation in cirrhosis. Gastroenterol Hepatol 2016;39:687-96. [PMID: 26775042 DOI: 10.1016/j.gastrohep.2015.10.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
84 Grąt M, Hołówko W, Wronka KM, Grąt K, Lewandowski Z, Kosińska I, Krasnodębski M, Wasilewicz M, Gałęcka M, Szachta P, Zborowska H, Patkowski W, Krawczyk M. The relevance of intestinal dysbiosis in liver transplant candidates. Transpl Infect Dis 2015;17:174-84. [PMID: 25728703 DOI: 10.1111/tid.12352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
85 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
86 Alsahhar JS, Rahimi RS. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. Current Opinion in Gastroenterology 2019;35:145-54. [DOI: 10.1097/mog.0000000000000527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Maslennikov R, Ivashkin V, Efremova I, Alieva A, Kashuh E, Tsvetaeva E, Poluektova E, Shirokova E, Ivashkin K. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. World J Hepatol 2021; 13(5): 557-570 [PMID: 34131470 DOI: 10.4254/wjh.v13.i5.557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Wiest R. The Gut Microbiome and Cirrhosis: Basic Aspects. In: de Franchis R, editor. Portal Hypertension VI. Cham: Springer International Publishing; 2016. pp. 139-68. [DOI: 10.1007/978-3-319-23018-4_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Ridlon JM, Devendran S, Alves JM, Doden H, Wolf PG, Pereira GV, Ly L, Volland A, Takei H, Nittono H, Murai T, Kurosawa T, Chlipala GE, Green SJ, Hernandez AG, Fields CJ, Wright CL, Kakiyama G, Cann I, Kashyap P, McCracken V, Gaskins HR. The 'in vivo lifestyle' of bile acid 7α-dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice. Gut Microbes 2020;11:381-404. [PMID: 31177942 DOI: 10.1080/19490976.2019.1618173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
90 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
91 Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
92 Sui G, Jia L, Quan D, Zhao N, Yang G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging (Albany NY) 2021;13:21309-24. [PMID: 34473644 DOI: 10.18632/aging.203460] [Reference Citation Analysis]
93 Ryu KH. [Gut Microbiota and Pancreatobiliary System]. Korean J Gastroenterol 2020;75:231-9. [PMID: 32448854 DOI: 10.4166/kjg.2020.75.5.231] [Reference Citation Analysis]
94 Prokopidis K, Witard OC. Understanding the role of smoking and chronic excess alcohol consumption on reduced caloric intake and the development of sarcopenia. Nutr Res Rev 2021;:1-10. [PMID: 34027849 DOI: 10.1017/S0954422421000135] [Reference Citation Analysis]
95 Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol 2018;53:691-700. [PMID: 29075899 DOI: 10.1007/s00535-017-1400-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
96 Gottlieb A, Canbay A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells 2019;8:E1358. [PMID: 31671697 DOI: 10.3390/cells8111358] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
97 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
98 Elaine Chen YF, Lai MW, Tsai CN, Lai JY, Yang YC, Chen SY. Association of gut microbiota composition and copy number variation with Kasai procedure outcomes in infants with biliary atresia. Pediatr Neonatol 2020;61:238-40. [PMID: 32098726 DOI: 10.1016/j.pedneo.2019.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Li W, Deng M, Gong J, Zhang X, Ge S, Zhao L. Sodium Acetate Inhibit TGF-β1-Induced Activation of Hepatic Stellate Cells by Restoring AMPK or c-Jun Signaling. Front Nutr 2021;8:729583. [PMID: 34660662 DOI: 10.3389/fnut.2021.729583] [Reference Citation Analysis]
100 Ahlawat S, Asha, Sharma KK. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol 2021;72:636-68. [PMID: 32472555 DOI: 10.1111/lam.13333] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
101 Souto PA, Marcotegui AR, Orbea L, Skerl J, Perazzo JC. Hepatic encephalopathy: Ever closer to its big bang. World J Gastroenterol 2016; 22(42): 9251-9256 [PMID: 27895414 DOI: 10.3748/wjg.v22.i42.9251] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
102 Liu X, Guo W, Cui S, Tang X, Zhao J, Zhang H, Mao B, Chen W. A Comprehensive Assessment of the Safety of Blautia producta DSM 2950. Microorganisms 2021;9:908. [PMID: 33922843 DOI: 10.3390/microorganisms9050908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318:G554-G573. [PMID: 31984784 DOI: 10.1152/ajpgi.00223.2019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
104 Gharechahi J, Kharazian ZA, Sarikhan S, Jouzani GS, Aghdasi M, Hosseini Salekdeh G. The dynamics of the bacterial communities developed in maize silage. Microb Biotechnol 2017;10:1663-76. [PMID: 28696065 DOI: 10.1111/1751-7915.12751] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
105 Pataky Z, Genton L, Spahr L, Lazarevic V, Terraz S, Gaïa N, Rubbia-brandt L, Golay A, Schrenzel J, Pichard C. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2016;61:2721-31. [DOI: 10.1007/s10620-016-4179-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
106 Wang Y, Pan CQ, Xing H. Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. Biomed Res Int 2019;2019:9726786. [PMID: 31886272 DOI: 10.1155/2019/9726786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
107 Le Guern R, Stabler S, Gosset P, Pichavant M, Grandjean T, Faure E, Karaca Y, Faure K, Kipnis E, Dessein R. Colonization resistance against multi-drug-resistant bacteria: a narrative review. J Hosp Infect 2021;118:48-58. [PMID: 34492304 DOI: 10.1016/j.jhin.2021.09.001] [Reference Citation Analysis]
108 Chen L, Li H, Chen Y, Yang Y. Probiotic Lactobacillus rhamnosus GG reduces mortality of septic mice by modulating gut microbiota composition and metabolic profiles. Nutrition 2020;78:110863. [DOI: 10.1016/j.nut.2020.110863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
109 Panasevich MR, Schuster CM, Phillips KE, Meers GM, Chintapalli SV, Wankhade UD, Shankar K, Butteiger DN, Krul ES, Thyfault JP, Rector RS. Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats. J Nutr Biochem 2017;46:125-36. [PMID: 28605664 DOI: 10.1016/j.jnutbio.2017.05.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
110 Li Y, Tang R, Leung PSC, Gershwin ME, Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev. 2017;16:885-896. [PMID: 28698093 DOI: 10.1016/j.autrev.2017.07.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 15.4] [Reference Citation Analysis]
111 Bi C, Xiao G, Liu C, Yan J, Chen J, Si W, Zhang J, Liu Z. Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer. Front Cell Dev Biol 2021;9:702414. [PMID: 34957088 DOI: 10.3389/fcell.2021.702414] [Reference Citation Analysis]
112 Xue M, Liang H, Zhou Z, Liu Y, He X, Zhang Z, Sun T, Yang J, Qin Y, Qin K. Effect of fucoidan on ethanol-induced liver injury and steatosis in mice and the underlying mechanism. Food Nutr Res 2021;65. [PMID: 33994911 DOI: 10.29219/fnr.v65.5384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci 2020;22:E199. [PMID: 33379148 DOI: 10.3390/ijms22010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
114 Huang YC, Wu BH, Chu YL, Chang WC, Wu MC. Effects of Tempeh Fermentation with Lactobacillus plantarum and Rhizopus oligosporus on Streptozotocin-Induced Type II Diabetes Mellitus in Rats. Nutrients 2018;10:E1143. [PMID: 30135362 DOI: 10.3390/nu10091143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
115 Wang N, Wang J, Zhang T, Huang L, Yan W, Lu L, Jia J, Tao Y, Cai W, Wang Y. Alterations of gut microbiota and serum bile acids are associated with parenteral nutrition-associated liver disease. J Pediatr Surg 2021;56:738-44. [PMID: 32732165 DOI: 10.1016/j.jpedsurg.2020.06.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
116 Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:756-765.e3. [PMID: 30036646 DOI: 10.1016/j.cgh.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
117 Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020;72:1003-27. [DOI: 10.1016/j.jhep.2020.01.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
118 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
119 Pose E, Solà E, Lozano JJ, Juanola A, Sidorova J, Zaccherini G, de Wit K, Uschner F, Tonon M, Kazankov K, Jiménez C, Campion D, Napoleone L, Ma AT, Carol M, Morales-Ruiz M, Alessandria C, Beuers U, Caraceni P, Francoz C, Durand F, Mookerjee RP, Trebicka J, Vargas V, Piano S, Watson H, Abraldes JG, Kamath PS, Davis MM, Ginès P; investigators of the LIVERHOPE Consortium. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatol Commun 2021. [PMID: 34964311 DOI: 10.1002/hep4.1881] [Reference Citation Analysis]
120 Kim JW, Lee JS, Kim JH, Jeong JW, Lee DH, Nam S. Comparison of Microbiota Variation in Korean Healthy Adolescents with Adults Suggests Notable Maturity Differences. OMICS 2018;22:770-8. [PMID: 30481125 DOI: 10.1089/omi.2018.0146] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Janssen AWF, Dijk W, Boekhorst J, Kuipers F, Groen AK, Lukovac S, Hooiveld GJEJ, Kersten S. ANGPTL4 promotes bile acid absorption during taurocholic acid supplementation via a mechanism dependent on the gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862:1056-67. [PMID: 28733267 DOI: 10.1016/j.bbalip.2017.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
122 Yang Y, Ai G, Wang M. Alcoholic liver disease and intestinal microecology. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 43-49 [DOI: 10.11569/wcjd.v27.i1.43] [Reference Citation Analysis]
123 Li Y, Han T. Mechanisms of susceptibility to bacterial infections in cirrhotic patients. Shijie Huaren Xiaohua Zazhi 2015; 23(22): 3560-3566 [DOI: 10.11569/wcjd.v23.i22.3560] [Reference Citation Analysis]
124 Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci Rep 2019;9:167. [PMID: 30655568 DOI: 10.1038/s41598-018-35367-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
125 Berthold DL, Jones KDJ, Udalova IA. Regional specialization of macrophages along the gastrointestinal tract. Trends Immunol 2021;42:795-806. [PMID: 34373208 DOI: 10.1016/j.it.2021.07.006] [Reference Citation Analysis]
126 Bjerg AT, Sørensen MB, Krych L, Hansen LH, Astrup A, Kristensen M, Nielsen DS. The effect of Lactobacillus paracasei subsp. paracasei L. casei W8® on blood levels of triacylglycerol is independent of colonisation. Benef Microbes 2015;6:263-9. [PMID: 25273547 DOI: 10.3920/BM2014.0033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
127 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
128 Burns GL, Hoedt EC, Walker MM, Talley NJ, Keely S. Physiological mechanisms of unexplained (functional) gastrointestinal disorders. J Physiol 2021. [PMID: 34705270 DOI: 10.1113/JP281620] [Reference Citation Analysis]
129 Glassner K, Quigley EM, Franco L, Victor DW 3rd. Autoimmune liver disease and the enteric microbiome. AIMS Microbiol 2018;4:334-46. [PMID: 31294219 DOI: 10.3934/microbiol.2018.2.334] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
130 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Fomenky BE, Do DN, Talbot G, Chiquette J, Bissonnette N, Chouinard YP, Lessard M, Ibeagha-Awemu EM. Direct-fed microbial supplementation influences the bacteria community composition of the gastrointestinal tract of pre- and post-weaned calves. Sci Rep 2018;8:14147. [PMID: 30237565 DOI: 10.1038/s41598-018-32375-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
132 Watt KD. The evolving role of the microbiome in liver failure and liver transplantation. Liver Transpl 2016;22:58-61. [PMID: 27588961 DOI: 10.1002/lt.24623] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
133 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver: Microbiota and the Liver. Liver Transpl 2018;24:539-50. [DOI: 10.1002/lt.25008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
134 Wang J, Qian T, Jiang J, Yang Y, Shen Z, Huang Y, Chen G, Zheng S, Dong R. Gut microbial profile in biliary atresia: a case‐control study. Journal of Gastroenterology and Hepatology 2019;35:334-42. [DOI: 10.1111/jgh.14777] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
135 Zhou Q, Jiang L, Qiu J, Pan Y, Swanda RV, Shi P, Li A, Zhang X. Oral Exposure to 1,4-Dioxane Induces Hepatic Inflammation in Mice: The Potential Promoting Effect of the Gut Microbiome. Environ Sci Technol 2020;54:10149-58. [DOI: 10.1021/acs.est.0c01543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Ozaki D, Kubota R, Maeno T, Abdelhakim M, Hitosugi N. Association between gut microbiota, bone metabolism, and fracture risk in postmenopausal Japanese women. Osteoporos Int 2021;32:145-56. [PMID: 33241467 DOI: 10.1007/s00198-020-05728-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
137 Mücke MM, Rüschenbaum S, Mayer A, Mücke VT, Schwarzkopf KM, Zeuzem S, Kehrmann J, Scholtysik R, Lange CM. Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. Gut Pathog 2020;12:51. [PMID: 33133240 DOI: 10.1186/s13099-020-00389-y] [Reference Citation Analysis]
138 Wang H, Shang X, Wan X, Xiang X, Mao Q, Deng G, Wu Y. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep 2016;6:38180. [PMID: 27905528 DOI: 10.1038/srep38180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
139 Nadim MK, Durand F, Kellum JA, Levitsky J, O’leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent J, Genyk YS. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology 2016;64:717-35. [DOI: 10.1016/j.jhep.2015.10.019] [Cited by in Crossref: 150] [Cited by in F6Publishing: 111] [Article Influence: 25.0] [Reference Citation Analysis]
140 Vaughn BP, Kaiser T, Staley C, Hamilton MJ, Reich J, Graiziger C, Singroy S, Kabage AJ, Sadowsky MJ, Khoruts A. A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. Clin Exp Gastroenterol. 2019;12:9-19. [PMID: 30666146 DOI: 10.2147/ceg.s186097] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
141 Bajaj JS, Thacker LR, Fagan A, White MB, Gavis EA, Hylemon PB, Brown R, Acharya C, Heuman DM, Fuchs M, Dalmet S, Sikaroodi M, Gillevet PM. Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. JCI Insight 2018;3:98019. [PMID: 29515036 DOI: 10.1172/jci.insight.98019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
142 Flemming JA, Mullin M, Lu J, Sarkar MA, Djerboua M, Velez MP, Brogly S, Terrault NA. Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study. Gastroenterology 2020;159:1752-1762.e10. [PMID: 32781083 DOI: 10.1053/j.gastro.2020.07.052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
143 Basson A, Trotter A, Rodriguez-Palacios A, Cominelli F. Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease. Front Immunol. 2016;7:290. [PMID: 27531998 DOI: 10.3389/fimmu.2016.00290] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
144 Bajaj JS, Salzman N, Acharya C, Takei H, Kakiyama G, Fagan A, White MB, Gavis EA, Holtz ML, Hayward M, Nittono H, Hylemon PB, Cox IJ, Williams R, Taylor-Robinson SD, Sterling RK, Matherly SC, Fuchs M, Lee H, Puri P, Stravitz RT, Sanyal AJ, Ajayi L, Le Guennec A, Atkinson RA, Siddiqui MS, Luketic V, Pandak WM, Sikaroodi M, Gillevet PM. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. JCI Insight 2019;4:133410. [PMID: 31751317 DOI: 10.1172/jci.insight.133410] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
145 Tuomisto S, Pessi T, Collin P, Vuento R, Aittoniemi J, Karhunen PJ. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol 2014;14:40. [PMID: 24564202 DOI: 10.1186/1471-230X-14-40] [Cited by in Crossref: 68] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
146 He Y, Mao C, Wen H, Chen Z, Lai T, Li L, Lu W, Wu H. Influence of ad Libitum Feeding of Piglets With Bacillus Subtilis Fermented Liquid Feed on Gut Flora, Luminal Contents and Health. Sci Rep 2017;7:44553. [PMID: 28291252 DOI: 10.1038/srep44553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
147 White AK, Smith RJ, Bigler CR, Brooke WF, Schauer PR. Head and neck manifestations of neurofibromatosis. Laryngoscope. 1986;96:732-737. [PMID: 3088347 DOI: 10.1249/jes.0000000000000183] [Cited by in Crossref: 106] [Cited by in F6Publishing: 65] [Article Influence: 2.9] [Reference Citation Analysis]
148 Zöhrer E, Resch B, Scharnagl H, Schlagenhauf A, Fauler G, Stojakovic T, Hofer N, Lang U, Jahnel J. Serum bile acids in term and preterm neonates: A case-control study determining reference values and the influence of early-onset sepsis. Medicine (Baltimore) 2016;95:e5219. [PMID: 27858868 DOI: 10.1097/MD.0000000000005219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
149 So SY, Wu Q, Leung KS, Kundi ZM, Savidge TC, El-Nezami H. Yeast β-glucan reduces obesity-associated Bilophila abundance and modulates bile acid metabolism in healthy and high-fat diet mouse models. Am J Physiol Gastrointest Liver Physiol 2021;321:G639-55. [PMID: 34643089 DOI: 10.1152/ajpgi.00226.2021] [Reference Citation Analysis]
150 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
151 Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, Itzkowitz S, Hu J. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016;43:790-801. [PMID: 26857969 DOI: 10.1111/apt.13552] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 12.0] [Reference Citation Analysis]
152 Ding L, Zhang LY, Shi HH, Wang CC, Jiang XM, Xue CH, Yanagita T, Zhang TT, Wang YM. Eicosapentaenoic Acid-Enriched Phosphoethanolamine Plasmalogens Alleviated Atherosclerosis by Remodeling Gut Microbiota to Regulate Bile Acid Metabolism in LDLR-/- Mice. J Agric Food Chem 2020;68:5339-48. [PMID: 32306729 DOI: 10.1021/acs.jafc.9b08296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
153 Wang X, Chen L, Wang H, Cai W, Xie Q. Modulation of bile acid profile by gut microbiota in chronic hepatitis B. J Cell Mol Med 2020;24:2573-81. [PMID: 31925905 DOI: 10.1111/jcmm.14951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
154 McCann SE, Hullar MAJ, Tritchler DL, Cortes-Gomez E, Yao S, Davis W, O'Connor T, Erwin D, Thompson LU, Yan L, Lampe JW. Enterolignan Production in a Flaxseed Intervention Study in Postmenopausal US Women of African Ancestry and European Ancestry. Nutrients 2021;13:919. [PMID: 33809130 DOI: 10.3390/nu13030919] [Reference Citation Analysis]
155 Capurso G, Lahner E. The interaction between smoking, alcohol and the gut microbiome. Best Pract Res Clin Gastroenterol. 2017;31:579-588. [PMID: 29195678 DOI: 10.1016/j.bpg.2017.10.006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 15.6] [Reference Citation Analysis]
156 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
157 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Tveter KM, Villa-Rodriguez JA, Cabales AJ, Zhang L, Bawagan FG, Duran RM, Roopchand DE. Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor. BMJ Open Diabetes Res Care 2020;8:e001386. [PMID: 32771984 DOI: 10.1136/bmjdrc-2020-001386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
159 Ishizaka A, Koga M, Mizutani T, Lim LA, Adachi E, Ikeuchi K, Ueda R, Aoyagi H, Tanaka S, Kiyono H, Matano T, Aizaki H, Yoshio S, Mita E, Muramatsu M, Kanto T, Tsutsumi T, Yotsuyanagi H. Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus. Viruses 2021;13:2101. [PMID: 34696531 DOI: 10.3390/v13102101] [Reference Citation Analysis]
160 Kieffer DA, Martin RJ, Adams SH. Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys. Adv Nutr 2016;7:1111-21. [PMID: 28140328 DOI: 10.3945/an.116.013219] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
161 Jia B, Park D, Hahn Y, Jeon CO. Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health. Gut Microbes 2020;11:1300-13. [PMID: 32329665 DOI: 10.1080/19490976.2020.1748261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
162 Watanabe K, Igarashi M, Li X, Nakatani A, Miyamoto J, Inaba Y, Sutou A, Saito T, Sato T, Tachibana N, Inoue H, Kimura I. Dietary soybean protein ameliorates high-fat diet-induced obesity by modifying the gut microbiota-dependent biotransformation of bile acids. PLoS One 2018;13:e0202083. [PMID: 30102711 DOI: 10.1371/journal.pone.0202083] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
163 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
164 Rocco A, Sgamato C, Compare D, Coccoli P, Nardone OM, Nardone G. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol 2021;9:748253. [PMID: 34900994 DOI: 10.3389/fcell.2021.748253] [Reference Citation Analysis]
165 Kurakawa T, Ogata K, Matsuda K, Tsuji H, Kubota H, Takada T, Kado Y, Asahara T, Takahashi T, Nomoto K. Diversity of Intestinal Clostridium coccoides Group in the Japanese Population, as Demonstrated by Reverse Transcription-Quantitative PCR. PLoS One 2015;10:e0126226. [PMID: 26000453 DOI: 10.1371/journal.pone.0126226] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
166 Ancona G, Alagna L, Lombardi A, Palomba E, Castelli V, Renisi G, Dondossola D, Iavarone M, Muscatello A, Gori A, Bandera A. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infect Immun 2021;89:e0037621. [PMID: 34460287 DOI: 10.1128/IAI.00376-21] [Reference Citation Analysis]
167 Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018;12:641-656. [PMID: 29806487 DOI: 10.1080/17474124.2018.1481747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
168 Liu Y, Li J, Jin Y, Zhao L, Zhao F, Feng J, Li A, Wei Y. Splenectomy Leads to Amelioration of Altered Gut Microbiota and Metabolome in Liver Cirrhosis Patients. Front Microbiol. 2018;9:963. [PMID: 29867867 DOI: 10.3389/fmicb.2018.00963] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
169 Connors J, Dunn KA, Allott J, Bandsma R, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. The relationship between fecal bile acids and microbiome community structure in pediatric Crohn's disease. ISME J 2020;14:702-13. [PMID: 31796936 DOI: 10.1038/s41396-019-0560-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
170 Iida N, Mizukoshi E, Yamashita T, Terashima T, Arai K, Seishima J, Kaneko S. Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. Int J Cancer. 2019;145:2701-2711. [PMID: 30980680 DOI: 10.1002/ijc.32339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
171 Knox NC, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN. The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. Am J Gastroenterol. 2019;114:1051-1070. [PMID: 31232832 DOI: 10.14309/ajg.0000000000000305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
172 Wang Y, Chen H, Chen Q, Jiao FZ, Zhang WB, Gong ZJ. The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPS/TLR4/MyD88 Pathway. Mediators Inflamm 2018;2018:7859601. [PMID: 29725271 DOI: 10.1155/2018/7859601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
173 Song M, Yang Q, Zhang F, Chen L, Su H, Yang X, He H, Liu F, Zheng J, Ling M, Lai X, Zhu X, Wang L, Gao P, Shu G, Jiang Q, Wang S. Hyodeoxycholic acid (HDCA) suppresses intestinal epithelial cell proliferation through FXR-PI3K/AKT pathway, accompanied by alteration of bile acids metabolism profiles induced by gut bacteria. FASEB J 2020;34:7103-17. [PMID: 32246800 DOI: 10.1096/fj.201903244R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
174 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
175 Sato K, Meng F, Fava G, Glaser S, Alpini G. Functional roles of gut bacteria imbalance in cholangiopathies. Liver Research 2019;3:40-5. [DOI: 10.1016/j.livres.2018.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
176 Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy and Nutrition Influences: A Narrative Review. Nutr Clin Pract 2020;35:36-48. [PMID: 31872484 DOI: 10.1002/ncp.10458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
177 Qiu X, Chen C, Chen X. Lipocalin 2 Deficiency Restrains Aging-Related Reshaping of Gut Microbiota Structure and Metabolism. Biomolecules 2021;11:1286. [PMID: 34572499 DOI: 10.3390/biom11091286] [Reference Citation Analysis]
178 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
179 Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 2017;3:101-13. [PMID: 28983453 DOI: 10.1007/s40495-017-0087-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
180 Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. The Lancet 2020;396:1689-702. [DOI: 10.1016/s0140-6736(20)30469-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 14.5] [Reference Citation Analysis]
181 Daquigan N, Seekatz AM, Greathouse KL, Young VB, White JR. High-resolution profiling of the gut microbiome reveals the extent of Clostridium difficile burden. NPJ Biofilms Microbiomes 2017;3:35. [PMID: 29214047 DOI: 10.1038/s41522-017-0043-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
182 Williams E, Chu C, DeMorrow S. A critical review of bile acids and their receptors in hepatic encephalopathy. Anal Biochem 2021;:114436. [PMID: 34715070 DOI: 10.1016/j.ab.2021.114436] [Reference Citation Analysis]
183 Lee DG, Hori S, Kohmoto O, Kitta S, Yoshida R, Tanaka Y, Shimizu H, Takahashi K, Nagura T, Uchino H, Fukiya S, Yokota A, Ishizuka S. Ingestion of difructose anhydride III partially suppresses the deconjugation and 7α-dehydroxylation of bile acids in rats fed with a cholic acid-supplemented diet. Biosci Biotechnol Biochem 2019;83:1329-35. [PMID: 30912732 DOI: 10.1080/09168451.2019.1597617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
184 Voiosu A, Wiese S, Voiosu T, Bendtsen F, Møller S. Bile acids and cardiovascular function in cirrhosis. Liver Int 2017;37:1420-30. [DOI: 10.1111/liv.13394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
185 Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol 2020;115:814-22. [PMID: 32250997 DOI: 10.14309/ajg.0000000000000604] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
186 Van der Merwe S, Chokshi S, Bernsmeier C, Albillos A. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S82-S100. [PMID: 34039494 DOI: 10.1016/j.jhep.2020.11.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
187 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
188 Raj AS, Shanahan ER, Tran CD, Bhat P, Fletcher LM, Vesey DA, Morrison M, Holtmann G, Macdonald GA. Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. Clin Transl Gastroenterol 2019;10:e00068. [PMID: 31373933 DOI: 10.14309/ctg.0000000000000068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
189 Ocvirk S, O'Keefe SJ. Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions. Curr Nutr Rep. 2017;6:315-322. [PMID: 29430336 DOI: 10.1007/s13668-017-0219-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
190 Liu N, Feng J, Lv Y, Liu Q, Deng J, Xia Y, Guo C, Zhou Y. Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study. Exp Ther Med 2019;18:4058-66. [PMID: 31611941 DOI: 10.3892/etm.2019.8011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
191 Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res. 2015;56:1085-1099. [PMID: 25210150 DOI: 10.1194/jlr.r054114] [Cited by in Crossref: 216] [Cited by in F6Publishing: 121] [Article Influence: 27.0] [Reference Citation Analysis]
192 Chen Z, Ruan J, Li D, Wang M, Han Z, Qiu W, Wu G. The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy. Front Cell Infect Microbiol 2020;10:595759. [PMID: 33553004 DOI: 10.3389/fcimb.2020.595759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
193 Wassenaar TM. Functional insights on probiotics activity in the gut from metagenomic data. Benef Microbes 2021;12:613-5. [PMID: 34674608 DOI: 10.3920/BM2021.x002] [Reference Citation Analysis]
194 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
195 Shen TD, Daniel SG, Patel S, Kaplan E, Phung L, Lemelle-Thomas K, Chau L, Herman L, Trisolini C, Stonelake A, Toal E, Khungar V, Bittinger K, Reddy KR, Wu GD. The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis. Gut Microbes 2021;13:1987781. [PMID: 34747331 DOI: 10.1080/19490976.2021.1987781] [Reference Citation Analysis]
196 Bajaj JS, Fagan A, Sikaroodi M, Kakiyama G, Takei H, Degefu Y, Pandak WM, Hylemon PB, Fuchs M, John B, Heuman DM, Gavis E, Nittono H, Patil R, Gillevet PM. Alterations in Skin Microbiomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:2581-2591.e15. [PMID: 30905718 DOI: 10.1016/j.cgh.2019.03.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
197 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
198 Grüner N, Mattner J. Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver-Gut Axis. Int J Mol Sci 2021;22:1397. [PMID: 33573273 DOI: 10.3390/ijms22031397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
199 Luo H, Wu H, Wang L, Xiao S, Lu Y, Liu C, Yu X, Zhang X, Wang Z, Tang L. Hepatoprotective effects of Cassiae Semen on mice with non-alcoholic fatty liver disease based on gut microbiota. Commun Biol 2021;4:1357. [PMID: 34862475 DOI: 10.1038/s42003-021-02883-8] [Reference Citation Analysis]
200 Potgieter M, Bester J, Kell DB, Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev 2015;39:567-91. [PMID: 25940667 DOI: 10.1093/femsre/fuv013] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 30.7] [Reference Citation Analysis]
201 Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 2016;64:2015-27. [PMID: 27639192 DOI: 10.1002/hep.28829] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 25.0] [Reference Citation Analysis]
202 Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y. Gut Dysbiosis Associated With Hepatitis C Virus Infection.Clin Infect Dis. 2018;67:869-877. [PMID: 29718124 DOI: 10.1093/cid/ciy205] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 23.3] [Reference Citation Analysis]
203 Li D, Wang P, Wang P, Hu X, Chen F. The gut microbiota: A treasure for human health. Biotechnology Advances 2016;34:1210-24. [DOI: 10.1016/j.biotechadv.2016.08.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 15.2] [Reference Citation Analysis]
204 Li JG, Wang CD, Tang ZH, Guo YQ, Zheng TC, Li YZ, You ZQ. The Gut Bacterial Community Composition of Wild Cervus albirostris (White-Lipped Deer) Detected by the 16S Ribosomal RNA Gene Sequencing. Curr Microbiol 2017;74:1100-7. [PMID: 28667467 DOI: 10.1007/s00284-017-1288-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
205 Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G. The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterol J. 2017;5:944-953. [PMID: 29163959 DOI: 10.1177/2050640617705576] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
206 DeMorrow S. Bile Acids in Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:117-24. [PMID: 30774268 DOI: 10.1016/j.jceh.2018.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
207 Jain V, Alexander EC, Burford C, Verma A, Dhawan A. Gut Microbiome: A Potential Modifiable Risk Factor in Biliary Atresia. J Pediatr Gastroenterol Nutr 2021;72:184-93. [PMID: 33427793 DOI: 10.1097/MPG.0000000000002973] [Reference Citation Analysis]
208 Rackayová V, Flatt E, Braissant O, Grosse J, Capobianco D, Mastromarino P, McMillin M, DeMorrow S, McLin VA, Cudalbu C. Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease. Sci Rep 2021;11:2269. [PMID: 33500487 DOI: 10.1038/s41598-021-81871-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
209 Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20(45): 16795-16810 [PMID: 25492994 DOI: 10.3748/wjg.v20.i45.16795] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
210 Yu L, Wang L, Wu X, Yi H. RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis. Commun Biol 2021;4:230. [PMID: 33603089 DOI: 10.1038/s42003-021-01747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Half E, Keren N, Reshef L, Dorfman T, Lachter I, Kluger Y, Reshef N, Knobler H, Maor Y, Stein A, Konikoff FM, Gophna U. Fecal microbiome signatures of pancreatic cancer patients. Sci Rep 2019;9:16801. [PMID: 31727922 DOI: 10.1038/s41598-019-53041-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
212 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
213 Wu S, Jin C, Wang Y, Fu Z, Jin Y. Exposure to the fungicide propamocarb causes gut microbiota dysbiosis and metabolic disorder in mice. Environmental Pollution 2018;237:775-83. [DOI: 10.1016/j.envpol.2017.10.129] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
214 McMillin M, Frampton G, Quinn M, Ashfaq S, de los Santos M 3rd, Grant S, DeMorrow S. Bile Acid Signaling Is Involved in the Neurological Decline in a Murine Model of Acute Liver Failure. Am J Pathol 2016;186:312-23. [PMID: 26683664 DOI: 10.1016/j.ajpath.2015.10.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
215 Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 2019;120:2713-20. [PMID: 30443932 DOI: 10.1002/jcb.27635] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
216 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
217 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
218 Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015;39:763-775. [PMID: 25872593 DOI: 10.1111/acer.12704] [Cited by in Crossref: 126] [Cited by in F6Publishing: 122] [Article Influence: 21.0] [Reference Citation Analysis]
219 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
220 Kato K, Nagao M, Miyamoto K, Oka K, Takahashi M, Yamamoto M, Matsumura Y, Kaido T, Uemoto S, Ichiyama S. Longitudinal Analysis of the Intestinal Microbiota in Liver Transplantation. Transplant Direct. 2017;3:e144. [PMID: 28405600 DOI: 10.1097/txd.0000000000000661] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
221 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, Gavis EA, Pandak WM, Nittono H, Hylemon PB, Boonma P, Haag A, Heuman DM, Fuchs M, John B, Sikaroodi M, Gillevet PM. Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology 2018;68:1549-58. [DOI: 10.1002/hep.30037] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
223 Chascsa DM, Ferré EMN, Hadjiyannis Y, Alao H, Natarajan M, Quinones M, Kleiner DE, Simcox TL, Chitsaz E, Rose SR, Hallgren A, Kampe O, Marko J, Ali RO, Auh S, Koh C, Belkaid Y, Lionakis MS, Heller T. APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort. Hepatology 2021;73:1088-104. [PMID: 32557834 DOI: 10.1002/hep.31421] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
224 Salic K, Kleemann R, Wilkins-Port C, McNulty J, Verschuren L, Palmer M. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One 2019;14:e0218459. [PMID: 31233523 DOI: 10.1371/journal.pone.0218459] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
225 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
226 Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes 2020;11:569-80. [PMID: 31696774 DOI: 10.1080/19490976.2019.1681861] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
227 Franzén O, Hu J, Bao X, Itzkowitz SH, Peter I, Bashir A. Improved OTU-picking using long-read 16S rRNA gene amplicon sequencing and generic hierarchical clustering. Microbiome 2015;3:43. [PMID: 26434730 DOI: 10.1186/s40168-015-0105-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
228 Wirth KM, Kizy S, Steer CJ. Liver Regeneration in the Acute Liver Failure Patient. Clin Liver Dis. 2018;22:269-287. [PMID: 29605066 DOI: 10.1016/j.cld.2018.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
229 Ottosson F, Brunkwall L, Smith E, Orho-Melander M, Nilsson PM, Fernandez C, Melander O. The gut microbiota-related metabolite phenylacetylglutamine associates with increased risk of incident coronary artery disease. J Hypertens 2020;38:2427-34. [PMID: 32665522 DOI: 10.1097/HJH.0000000000002569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
230 Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH, McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer 2020;147:2743-53. [PMID: 32406072 DOI: 10.1002/ijc.33051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
231 Dawson PA. Bile Formation and the Enterohepatic Circulation. Physiology of the Gastrointestinal Tract. Elsevier; 2018. pp. 931-56. [DOI: 10.1016/b978-0-12-809954-4.00041-4] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
232 Hamajima H, Matsunaga H, Fujikawa A, Sato T, Mitsutake S, Yanagita T, Nagao K, Nakayama J, Kitagaki H. Japanese traditional dietary fungus koji Aspergillus oryzae functions as a prebiotic for Blautia coccoides through glycosylceramide: Japanese dietary fungus koji is a new prebiotic. Springerplus 2016;5:1321. [PMID: 27563516 DOI: 10.1186/s40064-016-2950-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
233 Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002. [PMID: 27550547 DOI: 10.1038/srep32002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 124] [Article Influence: 19.0] [Reference Citation Analysis]
234 Tabibian JH, Varghese C, LaRusso NF, O'Hara SP. The enteric microbiome in hepatobiliary health and disease. Liver Int 2016;36:480-7. [PMID: 26561779 DOI: 10.1111/liv.13009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
235 Beraza N. Fibrosis and the intestinal microbiome; a focus on chronic liver disease. Curr Opin Pharmacol 2019;49:76-81. [PMID: 31670055 DOI: 10.1016/j.coph.2019.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
236 Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, Paziewska A, Goryca K, Karczmarski J, Rubel T, Wojtowicz W, Mlynarz P, Marczak L, Tomecki R, Mikula M, Ostrowski J. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes 2016;7:397-413. [PMID: 27662586 DOI: 10.1080/19490976.2016.1215805] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
237 Shavandi A, Saeedi P, Gérard P, Jalalvandi E, Cannella D, Bekhit AE. The role of microbiota in tissue repair and regeneration. J Tissue Eng Regen Med 2020;14:539-55. [PMID: 31845514 DOI: 10.1002/term.3009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
238 Lin H, An Y, Tang H, Wang Y. Alterations of Bile Acids and Gut Microbiota in Obesity Induced by High Fat Diet in Rat Model. J Agric Food Chem 2019;67:3624-32. [PMID: 30832480 DOI: 10.1021/acs.jafc.9b00249] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 15.7] [Reference Citation Analysis]
239 Fei Y, Chen Z, Han S, Zhang S, Zhang T, Lu Y, Berglund B, Xiao H, Li L, Yao M. Role of prebiotics in enhancing the function of next-generation probiotics in gut microbiota. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34323634 DOI: 10.1080/10408398.2021.1958744] [Reference Citation Analysis]
240 Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013;4:382-387. [PMID: 23851335 DOI: 10.4161/gmic.25723] [Cited by in Crossref: 174] [Cited by in F6Publishing: 171] [Article Influence: 19.3] [Reference Citation Analysis]
241 Yue H, Cai W, Li Y, Feng X, Dong P, Xue C, Wang J. A Novel Sialoglycopeptide from Gadus morhua Eggs Prevents Liver Fibrosis Induced by CCl4 via Downregulating FXR/FGF15 and TLR4/TGF-β/Smad Pathways. J Agric Food Chem 2021;69:13093-101. [PMID: 34714650 DOI: 10.1021/acs.jafc.1c05411] [Reference Citation Analysis]
242 Özdirik B, Müller T, Wree A, Tacke F, Sigal M. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int J Mol Sci 2021;22:6975. [PMID: 34203536 DOI: 10.3390/ijms22136975] [Reference Citation Analysis]
243 Wu Y, Li J, Qin X, Sun S, Xiao Z, Dong X, Shahid MS, Yin D, Yuan J. Proteome and microbiota analysis reveals alterations of liver-gut axis under different stocking density of Peking ducks. PLoS One 2018;13:e0198985. [PMID: 30365498 DOI: 10.1371/journal.pone.0198985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
244 Galié S, García-Gavilán J, Camacho-Barcía L, Atzeni A, Muralidharan J, Papandreou C, Arcelin P, Palau-Galindo A, Garcia D, Basora J, Arias-Vasquez A, Bulló M. Effects of the Mediterranean Diet or Nut Consumption on Gut Microbiota Composition and Fecal Metabolites and their Relationship with Cardiometabolic Risk Factors. Mol Nutr Food Res 2021;:e2000982. [PMID: 34331403 DOI: 10.1002/mnfr.202000982] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Pandak WM, Kakiyama G. The acidic pathway of bile acid synthesis: Not just an alternative pathway. Liver Res 2019;3:88-98. [PMID: 32015930 DOI: 10.1016/j.livres.2019.05.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
246 Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr Opin Lipidol 2016;27:148-54. [PMID: 26959704 DOI: 10.1097/MOL.0000000000000274] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
247 Wang Y, Gao X, Zhang X, Xiao Y, Huang J, Yu D, Li X, Hu H, Ge T, Li D, Zhang T. Gut Microbiota Dysbiosis Is Associated with Altered Bile Acid Metabolism in Infantile Cholestasis. mSystems 2019;4:e00463-19. [PMID: 31848302 DOI: 10.1128/mSystems.00463-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
248 Huynh DK, Selvanderan SP, Harley HA, Holloway RH, Nguyen NQ. Nutritional care in hospitalized patients with chronic liver disease. World J Gastroenterol 2015; 21(45): 12835-12842 [PMID: 26668507 DOI: 10.3748/wjg.v21.i45.12835] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
249 Ponziani FR, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F, Reddel S, Calvani R, Marzetti E, Sanguinetti M, Gasbarrini A, Pompili M. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018;48:1301-11. [PMID: 30345704 DOI: 10.1111/apt.15004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
250 D Goldenberg S, Merrick B. The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection. Ther Adv Infect Dis 2021;8:2049936120981526. [PMID: 33614028 DOI: 10.1177/2049936120981526] [Reference Citation Analysis]
251 Bajaj JS. The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014;5:397-403. [PMID: 24690956 DOI: 10.4161/gmic.28684] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
252 Younge N, Yang Q, Seed PC. Enteral High Fat-Polyunsaturated Fatty Acid Blend Alters the Pathogen Composition of the Intestinal Microbiome in Premature Infants with an Enterostomy. J Pediatr 2017;181:93-101.e6. [PMID: 27856001 DOI: 10.1016/j.jpeds.2016.10.053] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
253 Martin G, Kolida S, Marchesi JR, Want E, Sidaway JE, Swann JR. In Vitro Modeling of Bile Acid Processing by the Human Fecal Microbiota. Front Microbiol 2018;9:1153. [PMID: 29922256 DOI: 10.3389/fmicb.2018.01153] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
254 Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940-947. [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019] [Cited by in Crossref: 495] [Cited by in F6Publishing: 446] [Article Influence: 55.0] [Reference Citation Analysis]
255 Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res 2017;1:3-9. [PMID: 29104811 DOI: 10.1016/j.livres.2017.05.001] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 18.8] [Reference Citation Analysis]
256 Liu HX, Hu Y, Wan YJ. Microbiota and bile acid profiles in retinoic acid-primed mice that exhibit accelerated liver regeneration. Oncotarget 2016;7:1096-106. [PMID: 26701854 DOI: 10.18632/oncotarget.6665] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
257 Sultan S, El-Mowafy M, Elgaml A, Ahmed TAE, Hassan H, Mottawea W. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Front Physiol 2021;12:715506. [PMID: 34646151 DOI: 10.3389/fphys.2021.715506] [Reference Citation Analysis]
258 Guo Y, Bian X, Liu J, Zhu M, Li L, Yao T, Tang C, Ravichandran V, Liao P, Papadimitriou K, Yin J. Dietary Components, Microbial Metabolites and Human Health: Reading between the Lines. Foods 2020;9:E1045. [PMID: 32756378 DOI: 10.3390/foods9081045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
259 Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R; Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68:918-932. [PMID: 29572891 DOI: 10.1002/hep.29892] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
260 Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 33353145 DOI: 10.3390/cancers12123830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
261 Dong HS, Shen QB, Lan HY, Zhao W, Cao P, Chen P. Fecal Bile Acids Profile of Crewmembers Consuming the Same Space Food in a Spacecraft Simulator. Front Physiol 2021;12:593226. [PMID: 34658900 DOI: 10.3389/fphys.2021.593226] [Reference Citation Analysis]
262 Bajaj JS, Hays RA. Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis. Am J Gastroenterol 2019;114:1027-9. [DOI: 10.14309/ajg.0000000000000191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
263 Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, Lobysheva I, Plovier H, Essaghir A, Demoulin JB, Bouzin C, Pachikian BD, Cani PD, Staels B, Dessy C, Delzenne NM. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut 2018;67:271-83. [PMID: 28377388 DOI: 10.1136/gutjnl-2016-313316] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 16.6] [Reference Citation Analysis]
264 Pérez-Matute P, Oteo JA. Is it enough to eliminate hepatitis C virus to reverse the damage caused by the infection? World J Clin Infect Dis 2017; 7(1): 1-5 [DOI: 10.5495/wjcid.v7.i1.1] [Reference Citation Analysis]
265 Inoue T, Funatsu Y, Ohnishi M, Isogawa M, Kawashima K, Tanaka M, Moriya K, Kawaratani H, Momoda R, Iio E, Nakagawa H, Suzuki Y, Matsuura K, Fujiwara K, Nakajima A, Yoshiji H, Nakayama J, Tanaka Y. Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. Liver Int 2021. [PMID: 34411400 DOI: 10.1111/liv.15041] [Reference Citation Analysis]
266 Gómez-Hurtado I, Such J, Sanz Y, Francés R. Gut microbiota-related complications in cirrhosis. World J Gastroenterol 2014; 20(42): 15624-15631 [PMID: 25400446 DOI: 10.3748/wjg.v20.i42.15624] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
267 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Durán R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gómez M, Anstee QM, Bugianesi E. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut 2021:gutjnl-2020-322564. [PMID: 33541866 DOI: 10.1136/gutjnl-2020-322564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
268 Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
269 Cobbold JFL, Atkinson S, Marchesi JR, Smith A, Wai SN, Stove J, Shojaee-Moradie F, Jackson N, Umpleby AM, Fitzpatrick J, Thomas EL, Bell JD, Holmes E, Taylor-Robinson SD, Goldin RD, Yee MS, Anstee QM, Thursz MR. Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. Hepatol Res 2018;48:69-77. [PMID: 28425154 DOI: 10.1111/hepr.12904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
270 Camilleri M. Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol. 2014;8:49-61. [PMID: 24410472 DOI: 10.1586/17474124.2014.851599] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
271 Kim HN, Joo EJ, Cheong HS, Kim Y, Kim HL, Shin H, Chang Y, Ryu S. Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases. J Clin Med 2019;8:E1089. [PMID: 31344854 DOI: 10.3390/jcm8081089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
272 Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, Li D, Jia W. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 2017;15:120. [PMID: 29241453 DOI: 10.1186/s12915-017-0462-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 19.0] [Reference Citation Analysis]
273 Furukawa M, Moriya K, Nakayama J, Inoue T, Momoda R, Kawaratani H, Namisaki T, Sato S, Douhara A, Kaji K, Kitade M, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Tanaka Y, Yoshiji H. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.Hepatol Res. 2020;50:840-852. [PMID: 32346970 DOI: 10.1111/hepr.13509] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
274 Wei W, Wang HF, Zhang Y, Zhang YL, Niu BY, Yao SK. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol 2020; 26(45): 7153-7172 [PMID: 33362374 DOI: 10.3748/wjg.v26.i45.7153] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
275 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
276 Wang R, Cai Y, Li J, Yau SY, Lu W, Stubbs B, Su KP, Xu G, So KF, Lin K, Qi LW. Effects of aerobic exercise on gut microbiota in adolescents with subthreshold mood syndromes and healthy adolescents: A 12-week, randomized controlled trial. J Affect Disord 2021;293:363-72. [PMID: 34233229 DOI: 10.1016/j.jad.2021.06.025] [Reference Citation Analysis]
277 Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer. 2019;19:185. [PMID: 30819129 DOI: 10.1186/s12885-019-5391-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 16.7] [Reference Citation Analysis]
278 Zhou H, Zhou SY, Gillilland M 3rd, Li JY, Lee A, Gao J, Zhang G, Xu X, Owyang C. Bile acid toxicity in Paneth cells contributes to gut dysbiosis induced by high-fat feeding. JCI Insight 2020;5:138881. [PMID: 33055426 DOI: 10.1172/jci.insight.138881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
279 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 27.3] [Reference Citation Analysis]
280 Sun Y, Liu Z, Pi Z, Song F, Wu J, Liu S. Poria cocos could ameliorate cognitive dysfunction in APP/PS1 mice by restoring imbalance of Aβ production and clearance and gut microbiota dysbiosis. Phytother Res 2021. [PMID: 33432644 DOI: 10.1002/ptr.7014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Haange SB, Jehmlich N, Krügel U, Hintschich C, Wehrmann D, Hankir M, Seyfried F, Froment J, Hübschmann T, Müller S, Wissenbach DK, Kang K, Buettner C, Panagiotou G, Noll M, Rolle-Kampczyk U, Fenske W, von Bergen M. Gastric bypass surgery in a rat model alters the community structure and functional composition of the intestinal microbiota independently of weight loss. Microbiome 2020;8:13. [PMID: 32033593 DOI: 10.1186/s40168-020-0788-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
282 Zhang X, Zhu M, Xu B, Cui Y, Tian G, Shi Z, Ding M. Indirect electrochemical detection for total bile acids in human serum. Biosens Bioelectron 2016;85:563-7. [PMID: 27236139 DOI: 10.1016/j.bios.2016.05.055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
283 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
284 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Reference Citation Analysis]
285 Li R, Wang H, Shi Q, Wang N, Zhang Z, Xiong C, Liu J, Chen Y, Jiang L, Jiang Q. Effects of oral florfenicol and azithromycin on gut microbiota and adipogenesis in mice. PLoS One 2017;12:e0181690. [PMID: 28742883 DOI: 10.1371/journal.pone.0181690] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
286 Wankhade UD, Zhong Y, Kang P, Alfaro M, Chintapalli SV, Piccolo BD, Mercer KE, Andres A, Thakali KM, Shankar K. Maternal High-Fat Diet Programs Offspring Liver Steatosis in a Sexually Dimorphic Manner in Association with Changes in Gut Microbial Ecology in Mice. Sci Rep 2018;8:16502. [PMID: 30405201 DOI: 10.1038/s41598-018-34453-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
287 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
288 van Best N, Jansen PL, Rensen SS. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol Int. 2015;9:406-415. [PMID: 26067771 DOI: 10.1007/s12072-015-9640-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
289 Van Hul M, Karnik K, Canene-Adams K, De Souza M, Van den Abbeele P, Marzorati M, Delzenne NM, Everard A, Cani PD. Comparison of the effects of soluble corn fiber and fructooligosaccharides on metabolism, inflammation, and gut microbiome of high-fat diet-fed mice. Am J Physiol Endocrinol Metab 2020;319:E779-91. [PMID: 32830554 DOI: 10.1152/ajpendo.00108.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
290 Rojo D, Méndez-García C, Raczkowska BA, Bargiela R, Moya A, Ferrer M, Barbas C. Exploring the human microbiome from multiple perspectives: factors altering its composition and function. FEMS Microbiol Rev 2017;41:453-78. [PMID: 28333226 DOI: 10.1093/femsre/fuw046] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
291 Lang S, Fairfied B, Gao B, Duan Y, Zhang X, Fouts DE, Schnabl B. Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes 2020;12:1785251. [PMID: 32684075 DOI: 10.1080/19490976.2020.1785251] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
292 Ozato N, Saito S, Yamaguchi T, Katashima M, Tokuda I, Sawada K, Katsuragi Y, Kakuta M, Imoto S, Ihara K, Nakaji S. Blautia genus associated with visceral fat accumulation in adults 20-76 years of age. NPJ Biofilms Microbiomes 2019;5:28. [PMID: 31602309 DOI: 10.1038/s41522-019-0101-x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 25.3] [Reference Citation Analysis]
293 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Micó-Carnero M, Rojano-Alfonso C, Álvarez-Mercado AI, Gracia-Sancho J, Casillas-Ramírez A, Peralta C. Effects of Gut Metabolites and Microbiota in Healthy and Marginal Livers Submitted to Surgery. Int J Mol Sci 2020;22:E44. [PMID: 33375200 DOI: 10.3390/ijms22010044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
295 Bakonyi D, Hummel W. Cloning, expression, and biochemical characterization of a novel NADP+-dependent 7α-hydroxysteroid dehydrogenase from Clostridium difficile and its application for the oxidation of bile acids. Enzyme Microb Technol 2017;99:16-24. [PMID: 28193327 DOI: 10.1016/j.enzmictec.2016.12.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
296 Zhu Y, Zhang JY, Wei YL, Hao JY, Lei YQ, Zhao WB, Xiao YH, Sun AD. The polyphenol-rich extract from chokeberry (Aronia melanocarpa L.) modulates gut microbiota and improves lipid metabolism in diet-induced obese rats. Nutr Metab (Lond) 2020;17:54. [PMID: 32655675 DOI: 10.1186/s12986-020-00473-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
297 Kakiyama G, Muto A, Takei H, Nittono H, Murai T, Kurosawa T, Hofmann AF, Pandak WM, Bajaj JS. A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. J Lipid Res. 2014;55:978-990. [PMID: 24627129 DOI: 10.1194/jlr.d047506] [Cited by in Crossref: 69] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
298 Yang L, Li Y, Wang S, Bian X, Jiang X, Wu J, Wang K, Wang Q, Xia J, Jiang S, Zhuge A, Yuan Y, Li S, Li L. Western Diet Aggravated Carbon Tetrachloride-Induced Chronic Liver Injury by Disturbing Gut Microbiota and Bile Acid Metabolism. Mol Nutr Food Res 2021;65:e2000811. [PMID: 33458949 DOI: 10.1002/mnfr.202000811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
299 Zhao L, Lou H, Peng Y, Chen S, Zhang Y, Li X. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine 2019;66:526-37. [DOI: 10.1007/s12020-019-02103-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
300 Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli MV, Calanni F, Grimaldi M, Gasbarrini A. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309-325. [PMID: 26673000 DOI: 10.2147/ceg.s89999] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
301 Liu HX, Keane R, Sheng L, Wan YJ. Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol. 2015;63:1502-1510. [PMID: 26256437 DOI: 10.1016/j.jhep.2015.08.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
302 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
303 Bajaj JS, Kakiyama G, Cox IJ, Nittono H, Takei H, White M, Fagan A, Gavis EA, Heuman DM, Gilles HC, Hylemon P, Taylor-Robinson SD, Legido-Quigley C, Kim M, Xu J, Williams R, Sikaroodi M, Pandak WM, Gillevet PM. Alterations in gut microbial function following liver transplant. Liver Transpl 2018;24:752-61. [PMID: 29500907 DOI: 10.1002/lt.25046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
304 Li DS, Huang QF, Guan LH, Zhang HZ, Li X, Fu KL, Chen YX, Wan JB, Huang M, Bi HC. Targeted bile acids and gut microbiome profiles reveal the hepato-protective effect of WZ tablet (Schisandra sphenanthera extract) against LCA-induced cholestasis. Chin J Nat Med 2020;18:211-8. [PMID: 32245591 DOI: 10.1016/S1875-5364(20)30023-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Aoki R, Onuki M, Hattori K, Ito M, Yamada T, Kamikado K, Kim YG, Nakamoto N, Kimura I, Clarke JM, Kanai T, Hase K. Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. Microbiome 2021;9:188. [PMID: 34530928 DOI: 10.1186/s40168-021-01125-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Ocvirk S, Wilson AS, Posma JM, Li JV, Koller KR, Day GM, Flanagan CA, Otto JE, Sacco PE, Sacco FD, Sapp FR, Wilson AS, Newton K, Brouard F, DeLany JP, Behnning M, Appolonia CN, Soni D, Bhatti F, Methé B, Fitch A, Morris A, Gaskins HR, Kinross J, Nicholson JK, Thomas TK, O'Keefe SJD. A prospective cohort analysis of gut microbial co-metabolism in Alaska Native and rural African people at high and low risk of colorectal cancer. Am J Clin Nutr 2020;111:406-19. [PMID: 31851298 DOI: 10.1093/ajcn/nqz301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
307 Malagón M, Ramió-Pujol S, Serrano M, Serra-Pagès M, Amoedo J, Oliver L, Bahí A, Mas-de-Xaxars T, Torrealba L, Gilabert P, Miquel-Cusachs JO, García-Nimo L, Saló J, Guardiola J, Piñol V, Cubiella J, Castells A, Aldeguer X, Garcia-Gil J. Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers. Aliment Pharmacol Ther 2019;49:1410-20. [PMID: 31025420 DOI: 10.1111/apt.15251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
308 Shao JW, Ge TT, Chen SZ, Wang G, Yang Q, Huang CH, Xu LC, Chen Z. Role of bile acids in liver diseases mediated by the gut microbiome. World J Gastroenterol 2021; 27(22): 3010-3021 [PMID: 34168404 DOI: 10.3748/wjg.v27.i22.3010] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
310 Baldelli V, Scaldaferri F, Putignani L, Del Chierico F. The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases. Microorganisms 2021;9:697. [PMID: 33801755 DOI: 10.3390/microorganisms9040697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
311 Putignani L, Dallapiccola B. Foodomics as part of the host-microbiota-exposome interplay. J Proteomics 2016;147:3-20. [PMID: 27130534 DOI: 10.1016/j.jprot.2016.04.033] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
312 Llopis M, Cassard AM, Wrzosek L, Boschat L, Bruneau A, Ferrere G, Puchois V, Martin JC, Lepage P, Le Roy T, Lefèvre L, Langelier B, Cailleux F, González-castro AM, Rabot S, Gaudin F, Agostini H, Prévot S, Berrebi D, Ciocan D, Jousse C, Naveau S, Gérard P, Perlemuter G. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016;65:830-9. [DOI: 10.1136/gutjnl-2015-310585] [Cited by in Crossref: 230] [Cited by in F6Publishing: 214] [Article Influence: 32.9] [Reference Citation Analysis]
313 Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J Clin Med 2021;10:330. [PMID: 33477417 DOI: 10.3390/jcm10020330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
314 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Probiotics in hepatology: An update. World J Hepatol 2021; 13(9): 1154-1166 [PMID: 34630882 DOI: 10.4254/wjh.v13.i9.1154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
315 Zhang DY, Zhu L, Liu HN, Tseng YJ, Weng SQ, Liu TT, Dong L, Shen XZ. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 2019;13:2249-70. [PMID: 31308634 DOI: 10.2147/DDDT.S207277] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
316 Wisniewski PJ, Dowden RA, Campbell SC. Role of Dietary Lipids in Modulating Inflammation through the Gut Microbiota. Nutrients 2019;11:E117. [PMID: 30626117 DOI: 10.3390/nu11010117] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
317 Fiori J, Turroni S, Candela M, Gotti R. Assessment of gut microbiota fecal metabolites by chromatographic targeted approaches. J Pharm Biomed Anal 2020;177:112867. [PMID: 31614303 DOI: 10.1016/j.jpba.2019.112867] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
318 Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e5. [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001] [Cited by in Crossref: 349] [Cited by in F6Publishing: 334] [Article Influence: 87.3] [Reference Citation Analysis]
319 Kim AH, Lee Y, Kim E, Ji SC, Chung JY, Cho JY. Assessment of Oral Vancomycin-Induced Alterations in Gut Bacterial Microbiota and Metabolome of Healthy Men. Front Cell Infect Microbiol 2021;11:629438. [PMID: 34123865 DOI: 10.3389/fcimb.2021.629438] [Reference Citation Analysis]
320 Cuenca S, Sanchez E, Santiago A, El Khader I, Panda S, Vidal S, Camilo Nieto J, Juárez C, Sancho F, Guarner F. Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. J Innate Immun. 2014;6:263-271. [PMID: 24296725 DOI: 10.1159/000356454] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
321 Li R, Chen X, Liu Z, Chen Y, Liu C, Ye L, Xiao L, Yang Z, He J, Wang WJ, Qi H. Characterization of gut microbiota associated with clinical parameters in intrahepatic cholestasis of pregnancy. BMC Gastroenterol 2020;20:395. [PMID: 33225888 DOI: 10.1186/s12876-020-01510-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Zhang L, Chu J, Hao W, Zhang J, Li H, Yang C, Yang J, Chen X, Wang H. Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications. Mediators Inflamm 2021;2021:5110276. [PMID: 34447287 DOI: 10.1155/2021/5110276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
323 He J, Liu R, Zheng W, Guo H, Yang Y, Zhao R, Yao W. High ambient temperature exposure during late gestation disrupts glycolipid metabolism and hepatic mitochondrial function tightly related to gut microbial dysbiosis in pregnant mice. Microb Biotechnol 2021. [PMID: 34272826 DOI: 10.1111/1751-7915.13893] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-1524. [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020] [Cited by in Crossref: 487] [Cited by in F6Publishing: 468] [Article Influence: 60.9] [Reference Citation Analysis]
325 Ouald Chaib A, Levy EI, Ouald Chaib M, Vandenplas Y. The influence of the gastrointestinal microbiome on infant colic. Expert Rev Gastroenterol Hepatol 2020;14:919-32. [PMID: 32633578 DOI: 10.1080/17474124.2020.1791702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:543-51. [DOI: 10.1080/13543784.2018.1483333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
327 Ikegami T, Honda A. Reciprocal interactions between bile acids and gut microbiota in human liver diseases: Bile acids and gut microbiota. Hepatol Res 2018;48:15-27. [DOI: 10.1111/hepr.13001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
328 Cox IJ, Idilman R, Fagan A, Turan D, Ajayi L, Le Guennec AD, Taylor-Robinson SD, Karakaya F, Gavis E, Andrew Atkinson R, Williams R, Sikaroodi M, Nizam S, Gillevet PM, Bajaj JS. Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis. Liver Int 2020;40:416-27. [PMID: 31544308 DOI: 10.1111/liv.14256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
329 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
330 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
331 Phelan JP, Reen FJ, Caparros-Martin JA, O'Connor R, O'Gara F. Rethinking the bile acid/gut microbiome axis in cancer. Oncotarget 2017;8:115736-47. [PMID: 29383197 DOI: 10.18632/oncotarget.22803] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
332 Tranah TH, Kronsten VT, Shawcross DL. Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transpl 2021. [PMID: 34738724 DOI: 10.1002/lt.26353] [Reference Citation Analysis]
333 Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection. J Infect Dis 2021:jiab094. [PMID: 33598686 DOI: 10.1093/infdis/jiab094] [Reference Citation Analysis]
334 Urdaneta V, Casadesús J. Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts. Front Med (Lausanne) 2017;4:163. [PMID: 29043249 DOI: 10.3389/fmed.2017.00163] [Cited by in Crossref: 115] [Cited by in F6Publishing: 92] [Article Influence: 23.0] [Reference Citation Analysis]
335 Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014;66:948-83. [PMID: 25073467 DOI: 10.1124/pr.113.008201] [Cited by in Crossref: 402] [Cited by in F6Publishing: 380] [Article Influence: 57.4] [Reference Citation Analysis]
336 Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67:667-670. [PMID: 25095806 DOI: 10.1038/ja.2014.106] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
337 Bajaj JS. Microbiome and complications of liver disease. Clin Liver Dis (Hoboken) 2015;5:96-9. [PMID: 31040960 DOI: 10.1002/cld.460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Hang Z, Lei T, Zeng Z, Cai S, Bi W, Du H. Composition of intestinal flora affects the risk relationship between Alzheimer's disease/Parkinson's disease and cancer. Biomed Pharmacother 2022;145:112343. [PMID: 34864312 DOI: 10.1016/j.biopha.2021.112343] [Reference Citation Analysis]
339 Kakiyama G, Hylemon PB, Zhou H, Pandak WM, Heuman DM, Kang DJ, Takei H, Nittono H, Ridlon JM, Fuchs M. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014;306:G929-G937. [PMID: 24699327 DOI: 10.1152/ajpgi.00315.2013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 11.4] [Reference Citation Analysis]
340 Penney NC, Kinross J, Newton RC, Purkayastha S. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes (Lond). 2015;39:1565-1574. [PMID: 26081915 DOI: 10.1038/ijo.2015.115] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 12.9] [Reference Citation Analysis]
341 Clarembeau F, Bale G, Lanthier N. Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments. Clin Sci (Lond) 2020;134:2117-35. [PMID: 32820802 DOI: 10.1042/CS20200022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
342 Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, Smits WK. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Front Microbiol 2018;9:1242. [PMID: 29946308 DOI: 10.3389/fmicb.2018.01242] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
343 Guo X, Yang X, Li Q, Shen X, Zhong H, Yang Y. The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics. Front Pharmacol 2021;12:759095. [PMID: 34887760 DOI: 10.3389/fphar.2021.759095] [Reference Citation Analysis]
344 Gomez MV, Dutta M, Suvorov A, Shi X, Gu H, Mani S, Yue Cui J. Early Life Exposure to Environmental Contaminants (BDE-47, TBBPA, and BPS) Produced Persistent Alterations in Fecal Microbiome in Adult Male Mice. Toxicol Sci 2021;179:14-30. [PMID: 33078840 DOI: 10.1093/toxsci/kfaa161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
345 Scarpellini E, Fagoonee S, Rinninella E, Rasetti C, Aquila I, Larussa T, Ricci P, Luzza F, Abenavoli L. Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. J Clin Med 2020;9:E2488. [PMID: 32756323 DOI: 10.3390/jcm9082488] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
346 Hegyi P, Maléth J, Walters JR, Hofmann AF, Keely SJ. Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. Physiol Rev 2018;98:1983-2023. [PMID: 30067158 DOI: 10.1152/physrev.00054.2017] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 27.0] [Reference Citation Analysis]
347 Horvatits T, Drolz A, Rutter K, Roedl K, Langouche L, Van den Berghe G, Fauler G, Meyer B, Hülsmann M, Heinz G, Trauner M, Fuhrmann V. Circulating bile acids predict outcome in critically ill patients. Ann Intensive Care 2017;7:48. [PMID: 28466463 DOI: 10.1186/s13613-017-0272-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
348 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
349 Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, Tan J, Ching H, Coulter S, de Boer B, Christophersen CT, O'Sullivan TA, Morrison M, Jeffrey GP. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1356-65. [PMID: 32243703 DOI: 10.1111/liv.14453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
350 Watanabe M, Fukiya S, Yokota A. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J Lipid Res 2017;58:1143-52. [PMID: 28404640 DOI: 10.1194/jlr.M075143] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 9.2] [Reference Citation Analysis]
351 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
352 Molinero N, Ruiz L, Sánchez B, Margolles A, Delgado S. Intestinal Bacteria Interplay With Bile and Cholesterol Metabolism: Implications on Host Physiology. Front Physiol 2019;10:185. [PMID: 30923502 DOI: 10.3389/fphys.2019.00185] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 23.3] [Reference Citation Analysis]
353 Rao B, Lou J, Lu H, Liang H, Li J, Zhou H, Fan Y, Zhang H, Sun Y, Zou Y, Wu Z, Jiang Y, Ren Z, Yu Z. Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis. Front Cell Infect Microbiol 2021;11:656674. [PMID: 34094998 DOI: 10.3389/fcimb.2021.656674] [Reference Citation Analysis]
354 Jia ET, Liu ZY, Pan M, Lu JF, Ge QY. Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases. J Zhejiang Univ Sci B 2019;20:781-92. [PMID: 31489798 DOI: 10.1631/jzus.B1900073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
355 Ocvirk S, O'Keefe SJD. Dietary fat, bile acid metabolism and colorectal cancer. Semin Cancer Biol 2021;73:347-55. [PMID: 33069873 DOI: 10.1016/j.semcancer.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
356 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 47.0] [Reference Citation Analysis]
357 Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM. Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep. 2015;5:18559. [PMID: 26692421 DOI: 10.1038/srep18559] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
358 Macnaughtan J, Jalan R. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. Am J Gastroenterol. 2015;110:1399-1410; quiz 1411. [PMID: 26416191 DOI: 10.1038/ajg.2015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30:332-338. [PMID: 24625896 DOI: 10.1097/mog.0000000000000057] [Cited by in Crossref: 556] [Cited by in F6Publishing: 326] [Article Influence: 69.5] [Reference Citation Analysis]
360 Bajaj JS, Idilman R, Mabudian L, Hood M, Fagan A, Turan D, White MB, Karakaya F, Wang J, Atalay R, Hylemon PB, Gavis EA, Brown R, Thacker LR, Acharya C, Heuman DM, Sikaroodi M, Gillevet PM. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 2018;68:234-47. [DOI: 10.1002/hep.29791] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
361 Fling RR, Zacharewski TR. Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:12431. [PMID: 34830313 DOI: 10.3390/ijms222212431] [Reference Citation Analysis]
362 Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology 2020;71:1213-27. [PMID: 31442319 DOI: 10.1002/hep.30908] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 37.5] [Reference Citation Analysis]
363 Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm EJ. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One 2019;14:e0222881. [PMID: 31600222 DOI: 10.1371/journal.pone.0222881] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
364 Li D, Wang P, Wang P, Hu X, Chen F. Targeting the gut microbiota by dietary nutrients: A new avenue for human health. Critical Reviews in Food Science and Nutrition 2017;59:181-95. [DOI: 10.1080/10408398.2017.1363708] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
365 Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury - What is the link? J Hepatol. 2017;67:619-631. [PMID: 28712691 DOI: 10.1016/j.jhep.2017.04.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 14.4] [Reference Citation Analysis]
366 Sun Z, Huang C, Shi Y, Wang R, Fan J, Yu Y, Zhang Z, Zhu K, Li M, Ni Q, Chen Z, Zheng M, Yang Z. Distinct Bile Acid Profiles in Patients With Chronic Hepatitis B Virus Infection Reveal Metabolic Interplay Between Host, Virus and Gut Microbiome. Front Med (Lausanne) 2021;8:708495. [PMID: 34671614 DOI: 10.3389/fmed.2021.708495] [Reference Citation Analysis]
367 Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62:1260-1271. [PMID: 25820757 DOI: 10.1002/hep.27819] [Cited by in Crossref: 151] [Cited by in F6Publishing: 140] [Article Influence: 21.6] [Reference Citation Analysis]
368 Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol 2021;18:461-71. [PMID: 33432062 DOI: 10.1038/s41423-020-00601-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota. Gut Microbes. 2020;11:158-171. [PMID: 31595814 DOI: 10.1080/19490976.2019.1674124] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
370 Dosedělová V, Itterheimová P, Kubáň P. Analysis of bile acids in human biological samples by microcolumn separation techniques: A review. Electrophoresis 2021;42:68-85. [PMID: 32645223 DOI: 10.1002/elps.202000139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
371 Theriot CM, Bowman AA, Young VB. Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. mSphere 2016;1:e00045-15. [PMID: 27239562 DOI: 10.1128/mSphere.00045-15] [Cited by in Crossref: 184] [Cited by in F6Publishing: 144] [Article Influence: 30.7] [Reference Citation Analysis]
372 Chiang JY, Pathak P, Liu H, Donepudi A, Ferrell J, Boehme S. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. Dig Dis 2017;35:241-5. [PMID: 28249273 DOI: 10.1159/000450981] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
373 Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019;3:456-470. [PMID: 30976737 DOI: 10.1002/hep4.1331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
374 Vojinovic D, Radjabzadeh D, Kurilshikov A, Amin N, Wijmenga C, Franke L, Ikram MA, Uitterlinden AG, Zhernakova A, Fu J, Kraaij R, van Duijn CM. Relationship between gut microbiota and circulating metabolites in population-based cohorts. Nat Commun 2019;10:5813. [PMID: 31862950 DOI: 10.1038/s41467-019-13721-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
375 Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2:e94416. [PMID: 28978799 DOI: 10.1172/jci.insight.94416] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 14.4] [Reference Citation Analysis]
376 Chen T, Ding R, Chen X, Lu Y, Shi J, Lü Y, Tang B, Zhang W, Ye C, Yuan M, Yang Z. Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study. Bioengineered 2021;12:8233-46. [PMID: 34592890 DOI: 10.1080/21655979.2021.1982273] [Reference Citation Analysis]
377 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
378 Wu X, Yin S, Cheng C, Xu C, Peng J. Inclusion of Soluble Fiber During Gestation Regulates Gut Microbiota, Improves Bile Acid Homeostasis, and Enhances the Reproductive Performance of Sows. Front Vet Sci 2021;8:756910. [PMID: 34869730 DOI: 10.3389/fvets.2021.756910] [Reference Citation Analysis]
379 Kriaa A, Bourgin M, Potiron A, Mkaouar H, Jablaoui A, Gérard P, Maguin E, Rhimi M. Microbial impact on cholesterol and bile acid metabolism: current status and future prospects. J Lipid Res 2019;60:323-32. [PMID: 30487175 DOI: 10.1194/jlr.R088989] [Cited by in Crossref: 57] [Cited by in F6Publishing: 34] [Article Influence: 14.3] [Reference Citation Analysis]